The general mechanism of metastatic bone disease is the development of bone loss by the activation of osteoclasts via pro-osteoclast factors (IL-6, receptor activator of nuclear factor kappa-Β ligand, and parathyroid hormone-related protein) secreted by tumor cells. The gene discussed is IL6; the disease is neoplasm.